<?xml version='1.0' encoding='utf-8'?>
<document id="28836468"><sentence text="Effectiveness, Safety, and Costs of a Treatment Switch to Dolutegravir Plus Rilpivirine Dual Therapy in Treatment-Experienced HIV Patients."><entity charOffset="76-87" id="DDI-PubMed.28836468.s1.e0" text="Rilpivirine" /></sentence><sentence text="Evidence about the use of dolutegravir (DTG) and rilpivirine (RPV) as an antiretroviral therapy (ART) in treatment-experienced patients is scarce"><entity charOffset="26-38" id="DDI-PubMed.28836468.s2.e0" text="dolutegravir" /><entity charOffset="40-43" id="DDI-PubMed.28836468.s2.e1" text="DTG" /><entity charOffset="49-60" id="DDI-PubMed.28836468.s2.e2" text="rilpivirine" /><entity charOffset="62-65" id="DDI-PubMed.28836468.s2.e3" text="RPV" /><pair ddi="false" e1="DDI-PubMed.28836468.s2.e0" e2="DDI-PubMed.28836468.s2.e0" /><pair ddi="false" e1="DDI-PubMed.28836468.s2.e0" e2="DDI-PubMed.28836468.s2.e1" /><pair ddi="false" e1="DDI-PubMed.28836468.s2.e0" e2="DDI-PubMed.28836468.s2.e2" /><pair ddi="false" e1="DDI-PubMed.28836468.s2.e0" e2="DDI-PubMed.28836468.s2.e3" /><pair ddi="false" e1="DDI-PubMed.28836468.s2.e1" e2="DDI-PubMed.28836468.s2.e1" /><pair ddi="false" e1="DDI-PubMed.28836468.s2.e1" e2="DDI-PubMed.28836468.s2.e2" /><pair ddi="false" e1="DDI-PubMed.28836468.s2.e1" e2="DDI-PubMed.28836468.s2.e3" /><pair ddi="false" e1="DDI-PubMed.28836468.s2.e2" e2="DDI-PubMed.28836468.s2.e2" /><pair ddi="false" e1="DDI-PubMed.28836468.s2.e2" e2="DDI-PubMed.28836468.s2.e3" /></sentence><sentence text="" /><sentence text="To explore the effectiveness, safety, and costs of switching to a DTG plus RPV regimen in this population"><entity charOffset="66-68" id="DDI-PubMed.28836468.s4.e0" text="DTG" /><entity charOffset="75-77" id="DDI-PubMed.28836468.s4.e1" text="RPV" /><pair ddi="false" e1="DDI-PubMed.28836468.s4.e0" e2="DDI-PubMed.28836468.s4.e0" /><pair ddi="false" e1="DDI-PubMed.28836468.s4.e0" e2="DDI-PubMed.28836468.s4.e1" /></sentence><sentence text="" /><sentence text="This observational, prospective study included all treatment-experienced patients who switched to DTG plus RPV between November 2014 and July 2016"><entity charOffset="98-100" id="DDI-PubMed.28836468.s6.e0" text="DTG" /><entity charOffset="107-109" id="DDI-PubMed.28836468.s6.e1" text="RPV" /><pair ddi="false" e1="DDI-PubMed.28836468.s6.e0" e2="DDI-PubMed.28836468.s6.e0" /><pair ddi="false" e1="DDI-PubMed.28836468.s6.e0" e2="DDI-PubMed.28836468.s6.e1" /></sentence><sentence text=" Patients were excluded if resistance mutations to integrase inhibitors or RPV were found"><entity charOffset="75-77" id="DDI-PubMed.28836468.s7.e0" text="RPV" /></sentence><sentence text=" The effectiveness endpoint was the proportion of patients who achieved virological suppression (viral load [VL] &lt;50 copies/mL) at week 48 (W48)" /><sentence text=" Safety (incidence of adverse events leading to discontinuation and laboratory abnormalities), adherence, and costs were analyzed" /><sentence text="" /><sentence text="A total of 35 patients were included, and 91" /><sentence text="4% were virologically suppressed at baseline" /><sentence text=" Patients were treated with ART for a median of 14 years (interquartile range = 7-20)" /><sentence text=" At W48, 91" /><sentence text="4% of patients were virologically suppressed (95% CI = 77" /><sentence text="0-98" /><sentence text="2)" /><sentence text=" Two of the 3 patients not suppressed at baseline achieved undetectable VL at W48, and 2 patients discontinued DTG plus RPV (intolerance and a drug-drug interaction)"><entity charOffset="111-113" id="DDI-PubMed.28836468.s18.e0" text="DTG" /><entity charOffset="120-122" id="DDI-PubMed.28836468.s18.e1" text="RPV" /><pair ddi="false" e1="DDI-PubMed.28836468.s18.e0" e2="DDI-PubMed.28836468.s18.e0" /><pair ddi="false" e1="DDI-PubMed.28836468.s18.e0" e2="DDI-PubMed.28836468.s18.e1" /></sentence><sentence text=" None of the virologically suppressed patients at baseline showed virological rebound through W48" /><sentence text=" There were no significant changes in lipid, liver, and renal profiles" /><sentence text=" The proportion of patients with an ART adherence &gt;90% increased from 65" /><sentence text="6% to 93" /><sentence text="8% ( P = 0" /><sentence text="004)" /><sentence text=" The annual per-patient ART costs dropped by â‚¬665 ( P = 0" /><sentence text="265)" /><sentence text="" /><sentence text="Switching to DTG plus RPV seems to be an effective and safe strategy"><entity charOffset="13-15" id="DDI-PubMed.28836468.s28.e0" text="DTG" /><entity charOffset="22-24" id="DDI-PubMed.28836468.s28.e1" text="RPV" /><pair ddi="false" e1="DDI-PubMed.28836468.s28.e0" e2="DDI-PubMed.28836468.s28.e0" /><pair ddi="false" e1="DDI-PubMed.28836468.s28.e0" e2="DDI-PubMed.28836468.s28.e1" /></sentence><sentence text=" Significant improvements in patients' adherence and costs were achieved" /><sentence text="" /></document>